Angiolab, Inc. (XKON: 251280)

Market Cap	24.31B
Revenue	n/a
Net Income	n/a
Shares Out	2.99M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,219
Open	7,150.00
Previous Close	7,070.00
Day's Range	6,800.00 - 8,130.00
52-Week Range	3,000.00 - 9,000.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Angiolab

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 251280